Ketorolac Tromethiamine Tablets Targeting to Colon through Microbial Degradation and pH Dependence: Development and Roentogenographic Studies

Kalyani Chithaluru

Authors

Kalyani Chithaluru

Keywords:

colon target; hpmcp 55s; ketorolac tromethiamine; roentogenographic studies

Abstract

The present experiment was designed to develop colon specific drug delivery system of ketorolac tromethiamine (KT) for treatment of various colonic disorders. Matrix tablets were prepared by direct compression technique utilizing combination of guar gum with various types of biodegradable/pH dependent/hydrophilic retarders. Tablets evaluated for quality control tests and in-vitro liberation studies (24h). In vivo roentogenographic studies and stability studies performed for optimized formulation. KT containing combination of guar gum with HPMCP (Hypromellose Phthalate) 55S released negligible amount in 1.2 pH and 7.4 phosphate buffers and 70% released in 6.8 pH (simulated colonic fluid) whereas 95% of KT released in 6.8 pH buffer (ratcaecal content). In-vivo roentogenographic studies of optimized formulation (F10) showed location of the tablet at 30 mins, 3 h and 8 h was in stomach, caecum and ascending colon respectively. FT-IR & DSC reveals that no interaction between drug and used excipients.

Downloads

How to Cite

Ketorolac Tromethiamine Tablets Targeting to Colon through Microbial Degradation and pH Dependence: Development and Roentogenographic Studies. (2013). Global Journal of Medical Research, 13(B5), 25-32. https://medicalresearchjournal.org/index.php/GJMR/article/view/385

Download Citation

References

Helle Brøndsted, Jindr̆ich Kopec̆ek (1991) Hydrogels for site-specific oral drug delivery: synthesis and characterization. 12(6), 584-592.

Helle Brøndsted, Jindřich Kopeček (1992) Hydrogels for Site-Specific Drug Delivery to the Colon: In Vitro and in Vivo Degradation. 9(12), 1540-1545.

R Chan, D Pope, A Gilbett, P Sneta, J Baron, J Bennardjones (1983) Studies of two novel sulphasalazine analogs I.P. salazide and balsalazide. 28, 609-716.

A Goldstein, E Alter, J Seaman, Guar Gum (1993) Industrial gums, polysaccharides and their derivatives. 303-321.

Gilman Goodman (2001) Goodman and Gilman's the pharmacological basis of therapeutics. 10, 512-520.

T Hadjiioannou, G Christian, M Koupparis (1993) Quantitative Calculations in Pharmaceutical Practice and Research. 345-348.

Zhaopeng Hua, Go Kimura, Yoshiaki Ito, Syunsuke Mawatari, Tatuharu Shimokawa, Hiroshi Yoshikawa, Yukako Yoshikawa, Kanji Takada (1999) Technology to Obtain Sustained Release Characteristics of Drugs after Delivered to the Colon. 6(6), 439-448.

Bhavna Kumari, Anil Teotia, Prasad Thota, Piyush Kumar, Manoj Pandey, Rajeev Raghuvanshi (2010) Assessment of the Potency of Ceftiofur Sodium Powder through Validated Microbiological Method. 8(2), 53-61.

Renaat Kinget, Willbrord Kalala, Liesbeth Vervoort, Guy Van Den Mooter (1998) Colonic Drug Targeting. 6(2), 129-149.

Richard Korsmeyer, Robert Gurny, Eric Doelker, Pierre Buri, Nikolaos Peppas (1983) Mechanisms of solute release from porous hydrophilic polymers. 15(1), 25-35.

M Macneil, Hne Stevens (1990) Unknown Title.

M Muraoka, G Kimura, H Zhaopeng, K Takada (1998) Review: 5-aminosalicylic acid induces remission in ulcerative colitis. 3(5), 142-142.

Kiyoshi Niwa, Tomohiro Takaya, Tsuyoshi Morimoto, Kanji Takada (1995) Preparation and Evaluation of a Time-Controlled Release Capsule Made of Ethylcellulose for Colon Delivery of Drugs. 3(2), 83-89.

M Muthu (2006) Controlled release formulation in neurology practice. 201-216.

Purushotham Rao, K Prabhashankar, B, Ashok Kumar, Azeemuddin Khan, S Biradar, Patil Srishail (2003) Formulation and Roentgenographic Studies of Naproxen-pectin-based Matrix Tablets for Colon Drug Delivery. (76), 149-154.

Murray Saffran, G Kumar, Celin Savariar, Jeffrey Burnham, Frederick Williams, Douglas Neckers (1986) A New Approach to the Oral Administration of Insulin and Other Peptide Drugs. 233(4768), 1081-1084.

C Sninsky, D Cort, F Shanahan, B Powers, J Sessions, R Pruitt (1991) Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: A multicenter study. 115, 350-355.

A Tromm, T Griga, B May (1999) Oral mesalazine for the treatment Crohn's disease: Clinical efficacy with respect to pharmacokinetic Properties. 46, 778-780.

Peter Watts, Lisbeth Lllum (1997) Colonic Drug Delivery. 23(9), 893-913.